Clinical Trial Update: A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) [Phase 1]

View source ↗

Summary

A Phase 1 study (HEROEX-1) of NVL-330 in patients with advanced or metastatic HER2-altered non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• NVL-330 (NVL-330)

Snippet

Sponsor: Nuvalent Inc. | Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: RECRUITING